• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tumour grade does not change between primary and recurrent mammary carcinoma.

作者信息

Millis R R, Barnes D M, Lampejo O T, Egan M K, Smith P

机构信息

Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London, U.K.

出版信息

Eur J Cancer. 1998 Mar;34(4):548-53. doi: 10.1016/s0959-8049(97)10072-7.

DOI:10.1016/s0959-8049(97)10072-7
PMID:9713307
Abstract

The primary tumour grade in 115 patients with infiltrating ductal carcinoma of the breast was compared with the type of the ductal carcinoma in situ (DCIS) component and with the grade of 169 locally recurrent and metastatic lesions. 102 patients had axillary lymph node metastases at the time of primary surgery, 49 had subsequent recurrences and 36 had both. There was concordance of grade between the primary tumour and axillary lymph node metastases and with subsequent locally recurrent and metastatic lesions. The type of the DCIS component was also significantly associated with the grade of the infiltrating component. No evidence of progression of tumour grade between these phases of mammary carcinoma was found.

摘要

相似文献

1
Tumour grade does not change between primary and recurrent mammary carcinoma.
Eur J Cancer. 1998 Mar;34(4):548-53. doi: 10.1016/s0959-8049(97)10072-7.
2
Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.经粗针活检诊断的导管原位癌的浸润及腋窝淋巴结转移风险
Br J Surg. 2007 Aug;94(8):952-6. doi: 10.1002/bjs.5735.
3
Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.乳腺导管内癌(原位导管癌)。纯非浸润性肿瘤与包含不同比例浸润性癌的肿瘤的比较。
Cancer. 1994 Dec 1;74(11):2972-8. doi: 10.1002/1097-0142(19941201)74:11<2972::aid-cncr2820741113>3.0.co;2-z.
4
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.通过荧光原位杂交(FISH)在存档材料中检测Her-2/neu过表达和未表达的乳腺癌及其同步的良性、癌前和转移病变中Her-2/neu基因的扩增情况。
Mod Pathol. 2002 Feb;15(2):116-24. doi: 10.1038/modpathol.3880503.
5
Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases.保乳治疗原位导管癌后的局部复发。195例分析。
Cancer Radiother. 2013 Jun;17(3):196-201. doi: 10.1016/j.canrad.2013.01.011. Epub 2013 Mar 26.
6
Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation.导管原位癌(DCIS)的异质性:分级和亚型分析与局部复发及浸润性转化风险的关系。
Cancer Lett. 1995 Mar 23;90(1):97-102. doi: 10.1016/0304-3835(94)03683-a.
7
Is there a low-grade precursor pathway in breast cancer?乳腺癌是否存在低度恶性前体途径?
Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.
8
Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?前哨淋巴结微转移能否预测导管原位癌及伴微浸润导管原位癌的复发风险?
Am J Surg. 2008 Oct;196(4):566-8. doi: 10.1016/j.amjsurg.2008.06.011. Epub 2008 Aug 29.
9
Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.微浸润性乳腺癌:单机构经验的临床病理分析
Cancer. 2000 Mar 15;88(6):1403-9.
10
Cancerization of lobules and atypical ductal hyperplasia adjacent to ductal carcinoma in situ of the breast.乳腺导管原位癌旁小叶的癌变及非典型导管增生
Am J Clin Pathol. 1998 Sep;110(3):357-67. doi: 10.1093/ajcp/110.3.357.

引用本文的文献

1
Tools to Guide Radiation Oncologists in the Management of DCIS.指导放射肿瘤学家管理导管原位癌的工具。
Healthcare (Basel). 2024 Apr 6;12(7):795. doi: 10.3390/healthcare12070795.
2
Imaging Changes and Outcomes of Patients Undergoing Active Monitoring for Ductal Carcinoma In Situ: Seven-Year Follow-up Study.行影像学监测的导管原位癌患者的影像学变化和结局:7 年随访研究。
Acad Radiol. 2024 Jul;31(7):2654-2662. doi: 10.1016/j.acra.2023.12.021. Epub 2024 Jan 5.
3
Is DCIS breast cancer, and how do I treat it?DCIS 是乳腺癌吗?我应该如何治疗?
Curr Treat Options Oncol. 2013 Mar;14(1):75-87. doi: 10.1007/s11864-012-0217-1.
4
A comparison of clinicopathological features and molecular markers in british and nigerian women with breast cancer.英国和尼日利亚乳腺癌女性患者的临床病理特征及分子标志物比较
Clin Med Oncol. 2008;2:347-51. doi: 10.4137/cmo.s474. Epub 2008 Apr 24.
5
Genomic heterogeneity of breast tumor pathogenesis.乳腺肿瘤发病机制的基因组异质性。
Clin Med Oncol. 2009 Jul 29;3:77-85. doi: 10.4137/cmo.s2946.
6
Are ipsilateral breast tumour invasive recurrences in young (< or =40 years) women more aggressive than their primary tumours?年轻(≤40岁)女性同侧乳腺肿瘤浸润性复发是否比其原发肿瘤更具侵袭性?
Br J Cancer. 2007 Oct 22;97(8):1046-52. doi: 10.1038/sj.bjc.6603991. Epub 2007 Sep 18.
7
A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.使用阵列比较基因组杂交技术对浸润性导管癌和小叶癌中的16号染色体q进行的综合研究。
Oncogene. 2006 Oct 19;25(49):6544-53. doi: 10.1038/sj.onc.1209659. Epub 2006 May 15.
8
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast.乳腺单纯导管原位癌治疗后原位复发及浸润性癌的分级
Br J Cancer. 2004 Apr 19;90(8):1538-42. doi: 10.1038/sj.bjc.6601704.
9
Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry.通过比较基因组杂交(CGH)和免疫组织化学揭示具有癌变过程中假定分级进展的一组乳腺癌的解读。
Br J Cancer. 2004 Apr 5;90(7):1422-8. doi: 10.1038/sj.bjc.6601658.
10
Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma.肿瘤组织学分级在原发性和复发性浸润性乳腺癌之间可能会发生变化。
J Clin Pathol. 2002 Apr;55(4):293-7. doi: 10.1136/jcp.55.4.293.